Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Investments: 2019-2024

Historic Long-Term Investments for BridgeBio Pharma (BBIO) over the last 2 years, with Dec 2024 value amounting to $143.7 million.

  • BridgeBio Pharma's Long-Term Investments fell 42.55% to $92.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.2 million, marking a year-over-year decrease of 42.55%. This contributed to the annual value of $143.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Long-Term Investments is $143.7 million, which was up 361.56% from $31.1 million recorded in FY2019.
  • BridgeBio Pharma's Long-Term Investments' 5-year high stood at $143.7 million during FY2024, with a 5-year trough of $143.7 million in FY2024.
  • Over the past 1 years, BridgeBio Pharma's median Long-Term Investments value was $143.7 million (recorded in 2024), while the average stood at $143.7 million.